Biotricity Inc.
Find Ratings ReportsBIOTRICITY INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the subsector, the net income growth has not. BIOTRICITY INC has very weak liquidity. Currently, the Quick Ratio is 0.09 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 72.63% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 2.97 | 2.46 |
EBITDA ($mil) | -1.28 | -3.84 |
EBIT ($mil) | -1.28 | -3.84 |
Net Income ($mil) | -2.81 | -4.52 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 0.09 | 0.45 |
Total Assets ($mil) | 5.49 | 6.65 |
Total Debt ($mil) | 22.59 | 17.54 |
Equity ($mil) | -26.73 | -15.48 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 72.96 | 57.07 |
EBITDA Margin | -43.08 | -155.97 |
Operating Margin | -43.12 | -156.02 |
Sales Turnover | 2.12 | 1.36 |
Return on Assets | -265.84 | -294.82 |
Return on Equity | 0.0 | 0.0 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 0.21 | 0.66 |
Debt/Capital | -5.46 | 8.51 |
Interest Expense | 1.21 | 0.46 |
Interest Coverage | -1.06 | -8.27 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 9.42 | 8.71 |
Div / share | 0.0 | 0.0 |
EPS | -0.34 | -0.54 |
Book value / share | -2.84 | -1.78 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 67294.0 | 23864.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BTCY NM | Peers 53.34 | BTCY NM | Peers 44.47 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. BTCY's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BTCY's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
BTCY NM | Peers 26.06 | BTCY NA | Peers 1.95 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. BTCY's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
BTCY NM | Peers 23.59 | BTCY 25.00 | Peers 123.02 | |||||||||||||||||||||
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BTCY's P/B is negative making this valuation measure meaningless. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, BTCY is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
BTCY 0.99 | Peers 14.13 | BTCY 28.54 | Peers 27.20 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BTCY is trading at a significant discount to its subsector on this measurement. |
Average. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share. BTCY is keeping pace with its peers on the basis of sales growth. |
|||||||||||||||||||||||